MERIDIAN, Idaho, Jan. 16 /PRNewswire-FirstCall/ -- RxElite Inc., (OTC:RXEI) (BULLETIN BOARD: RXEI) a developer, manufacturer, and marketer of specialty generic prescription drug products, announced today that Shannon M. Stith has joined the company as Vice President of Finance and Principal Financial Officer. Mrs. Stith joins RxElite from her current position as the Vice President and Chief Financial Officer at PCS Edventures!.com, Inc. "We are delighted to add a person of Shannon's caliber to our team and we look forward to her contributions to help take us to the next level. Her hiring is consistent with our strategy of building an excellent team to manage our role as the vendor of choice for generic drugs," commented Jonathan Houssian, the CEO and founder of RxElite. Prior to working at PCS Edventures!.com, Mrs. Stith was a Chief Accountant for Washington Group International in the financial reporting department -- internal reporting. She brings with her extensive knowledge of cash management skills, capital project evaluation, SOX compliance and implementation, GAAP knowledge, and financial reporting expertise. She graduated in from Boise State University with a Bachelor of Business Administration in Finance and a Masters of Business Administration in 2002 and 2003, respectively. She is a member of the National Federation of Paralegals, Idaho CPA Society, and Executive Women International. About RxElite, Inc. RxElite, Inc. develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs), and transdermal patch products. Safe Harbor Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving known and unknown risks, delays, and uncertainties that may cause our actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks, delays, and uncertainties include, but are not limited to: risks associated with the uncertainty of future financial results, our reliance on our sole supplier, the limited diversification of our product offerings, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements. Contact: Corporate Information Ph: (208) 288-5550 Toll Free: (800) 414-1901 Fax: (208) 288-1191 Investor Relations Charlie Forshee, 215-885-4981 Segue Ventures LLC DATASOURCE: RxElite Inc. CONTACT: Corporate Information of RxElite Inc., +1-208-288-5550, or 1-800-414-1901, or fax, +1-208-288-1191; or Investor Relations, Charlie Forshee of Segue Ventures LLC, +1-215-885-4981, , for RxElite Inc. Web site: http://www.rxelite.com/

Copyright